Stockreport

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF SAN DIEGO, January 13, 2026 BUSINESS WIRE )--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended th [Read more]